Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.62

€0.62

0.480%
0.003
0.480%
€8.89
 
04.07.25 / Tradegate WKN: A2PHD4 / Symbol: IMUX / Name: Immunic / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Your prediction

Immunic Inc. Stock

The Immunic Inc. stock is trending slightly upwards today, with an increase of €0.003 (0.480%) compared to yesterday's price.
With 20 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 8 € there is potential for a 1194.5% increase which would mean more than doubling the current price of 0.62 € for Immunic Inc..
So far the community has only identified positive things for Immunic Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Immunic Inc. in the next few years

Pros
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Immunic Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Immunic Inc. 0.480% 3.691% -8.715% -42.512% -38.872% -81.295% -94.672%
NanoViricides Inc. -0.860% -0.862% -9.449% -27.673% -23.333% -35.266% -81.890%
Actinium Pharmaceuticals Inc. 3.400% -1.448% -18.005% -81.730% 6.429% -74.145% -85.832%
Ocuphire Pharma Inc. 0.950% -0.476% -6.271% -43.216% -24.595% -54.212% -

Comments

Prediction Buy
Perf. (%) 1.64%
Target price 8.599
Change
Ends at 25.06.26

Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -11.71%
Target price 8.759
Change
Ends at 05.06.26

Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -11.71%
Target price 8.887
Change
Ends at 29.05.26

Immunic, Inc. (NASDAQ: IMUX) had its price target lowered by analysts at D. Boral Capital from $17.00 to $10.00. They now have a "buy" rating on the stock.
Ratings data for IMUX provided by MarketBeat
Show more

News

EQS-News: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in  Relapsing-Remitting Multiple Sclerosis
EQS-News: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
EQS-News: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
EQS-News: Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
EQS-News: Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
EQS-News: Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
EQS-News: Immunic to Participate in Investor, Scientific and Industry Conferences in June
EQS-News: Immunic to Participate in Investor, Scientific and Industry Conferences in June
EQS-News: Immunic to Participate in Investor, Scientific and Industry Conferences in June